Beckman Coulter brings the productivity and efficiency benefits of large volume hematology analyzers to small- and medium-sized labs

Beckman Coulter, a global leader in clinical diagnostics, announced today the launch of the DxH 560 AL, a tabletop analyzer geared to reduce the time and resource constraints faced by small to mid-sized laboratories. With the analyzer's Auto-Loading functionality, closed tube aspiration and walkaway capabilities, users can continually add up to 50 samples, provide safety against blood-borne pathogens and spend less time on manual instrument tasks. Compactly designed, the DxH 560 AL uses ~30% less counter space than other analyzers in its class.

Smaller labs can now reap the same efficiency and productivity benefits as larger labs without blowing the budget.

The DxH 560 AL delivers results in 60 seconds or less, and is the ideal instrument to use with difficult-to-draw patients (infants, oncology and elderly) as it only needs a 17 μL sample – less than a drop of blood, one of the smallest aspiration volumes on the market. The analyzer also provides industry-leading privacy and security features including customizable user login, paperless data management and fully traceable automated timeouts that guards patient electronic personal health information.

"With proven performance and low-cost to operate, the DxH 560 AL includes the analytical strengths and data management capabilities of high-throughput analyzers in a small footprint," said Peter Soltani , Ph.D., senior vice president and general manager of hematology at Beckman Coulter. "The industry-leading functionality and auto-load capabilities of the DxH 560 AL enables smaller labs to reap the same efficiency and productivity benefits as their larger counterparts without blowing the budget."

The DxH 560 AL is part of Beckman Coulter's DxH 500 series of small footprint tabletop hematology analyzers, including the recently launched DxH 500 and the award winning DxH 520*. The full DxH 500 series of analyzers include dynamic gating for its 5-part differential, eliminating rejected results and lowering manual interventions.

Beckman Coulter's DxH 560 AL builds on the organization's strength in hematology innovation and complements its broad spectrum of hematology analyzers, including the award winning DxH 690T** for mid-volume, DxH 900 for high-volume and DxH connected workcell solutions for ultra-high-volume facilities. For more information on the DxH 560 AL, or the full DxH 500 series, visit https://www.beckmancoulter.com/en/products/hematology .

About Beckman Coulter
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology and the passion and creativity of our teams to enhance the diagnostic laboratory's role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter is headquartered in Brea, Calif. , and has more than 11,000 global associates working diligently to make the world a healthier place.

* Winner of the 2019 SelectScience Scientist's Choice Award for Best News Clinical Instrumentation
**Winner of the 2020 Frost & Sullivan 2020 Global Hematology Testing New Product Innovation Award

© 2021 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/beckman-coulter-brings-the-productivity-and-efficiency-benefits-of-large-volume-hematology-analyzers-to-small--and-medium-sized-labs-301214191.html

SOURCE Beckman Coulter Diagnostics

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Cardiologist wearing virtual reality glasses.

Top 3 Medical Device ETFs for Investors in 2026

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...

Interactive Chart

Latest Press Releases

Related News